MA33899B1 - Procedes et regimes a faible dose pour des troubles des globules rouges - Google Patents

Procedes et regimes a faible dose pour des troubles des globules rouges

Info

Publication number
MA33899B1
MA33899B1 MA35032A MA35032A MA33899B1 MA 33899 B1 MA33899 B1 MA 33899B1 MA 35032 A MA35032 A MA 35032A MA 35032 A MA35032 A MA 35032A MA 33899 B1 MA33899 B1 MA 33899B1
Authority
MA
Morocco
Prior art keywords
disorders
regimes
low dose
dose methods
fstale
Prior art date
Application number
MA35032A
Other languages
Arabic (ar)
English (en)
Inventor
Susan Perrine
Ronald J Berenson
Douglas V Faller
Original Assignee
Hemaquest Pharmaceuticals Inc
Univ Boston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hemaquest Pharmaceuticals Inc, Univ Boston filed Critical Hemaquest Pharmaceuticals Inc
Publication of MA33899B1 publication Critical patent/MA33899B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Abstract

L'invention porte sur des procédés et des régimes à faibles doses pour augmenter les taux d'hémoglobine fstale dans des patients présentant des troubles des globules rouges, tels que la bêta-thalassémie, l'anémie falciforme, d'autres anémies, ou une perte de sang. Les taux d'hémoglobine fstale et totale et les comptages des globules rouges sont augmentés par l'administration de 2,2-diméthylbutyrate (dmb) seul ou en combinaison avec de l'hydroxyurée, de la décitabine ou un inhibiteur de hdac. Le traitement peut être poursuivi pendant au moins deux semaines.
MA35032A 2009-12-08 2010-12-08 Procedes et regimes a faible dose pour des troubles des globules rouges MA33899B1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US26772709P 2009-12-08 2009-12-08
US29565010P 2010-01-15 2010-01-15
US30637610P 2010-02-19 2010-02-19
US31209010P 2010-03-09 2010-03-09
US36732610P 2010-07-23 2010-07-23
US41136910P 2010-11-08 2010-11-08
PCT/US2010/059584 WO2011072086A1 (fr) 2009-12-08 2010-12-08 Procédés et régimes à faible dose pour traiter des troubles des globules rouges

Publications (1)

Publication Number Publication Date
MA33899B1 true MA33899B1 (fr) 2013-01-02

Family

ID=44145905

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35032A MA33899B1 (fr) 2009-12-08 2010-12-08 Procedes et regimes a faible dose pour des troubles des globules rouges

Country Status (7)

Country Link
US (1) US8618068B2 (fr)
EP (1) EP2509418A4 (fr)
CN (1) CN102802412A (fr)
IL (1) IL220040A0 (fr)
MA (1) MA33899B1 (fr)
TN (1) TN2012000270A1 (fr)
WO (1) WO2011072086A1 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US10083273B2 (en) 2005-07-29 2018-09-25 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US10081839B2 (en) 2005-07-29 2018-09-25 Natera, Inc System and method for cleaning noisy genetic data and determining chromosome copy number
ES2620431T3 (es) 2008-08-04 2017-06-28 Natera, Inc. Métodos para la determinación de alelos y de ploidía
US8825412B2 (en) 2010-05-18 2014-09-02 Natera, Inc. Methods for non-invasive prenatal ploidy calling
EP2473638B1 (fr) 2009-09-30 2017-08-09 Natera, Inc. Méthode non invasive de détermination d'une ploïdie prénatale
WO2011113013A2 (fr) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Procédés et compositions pour le traitement d'états viraux ou induits par des virus
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US11326208B2 (en) 2010-05-18 2022-05-10 Natera, Inc. Methods for nested PCR amplification of cell-free DNA
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US20120016686A1 (en) * 2010-07-13 2012-01-19 Cerner Innovation, Inc. Inpatient blood management
EP2656263B1 (fr) 2010-12-22 2019-11-06 Natera, Inc. Procédés de recherche de paternité prénatale, non invasive
JP6153874B2 (ja) 2011-02-09 2017-06-28 ナテラ， インコーポレイテッド 非侵襲的出生前倍数性呼び出しのための方法
US8975293B2 (en) * 2011-05-26 2015-03-10 Regents Of The University Of Michigan Epigenetic co-repressors of the gamma-globin gene and methods of using same
WO2013055985A1 (fr) * 2011-10-12 2013-04-18 Children's Medical Center Corporation Compositions combinatoires et méthodes de traitement d'hémoglobinopathies
ITRM20120405A1 (it) 2012-08-09 2014-02-10 C N C C S Scarl Collezione Naziona Le Dei Compost Compounds for use in the treatment of disorders that are ameliorated by inhibition of hdac
US20140065621A1 (en) * 2012-09-04 2014-03-06 Natera, Inc. Methods for increasing fetal fraction in maternal blood
SG10202110062SA (en) 2012-11-27 2021-11-29 Childrens Medical Center Targeting Bcl11a Distal Regulatory Elements for Fetal Hemoglobin Reinduction
US10577655B2 (en) 2013-09-27 2020-03-03 Natera, Inc. Cell free DNA diagnostic testing standards
US9499870B2 (en) 2013-09-27 2016-11-22 Natera, Inc. Cell free DNA diagnostic testing standards
US10262755B2 (en) 2014-04-21 2019-04-16 Natera, Inc. Detecting cancer mutations and aneuploidy in chromosomal segments
RU2717641C2 (ru) 2014-04-21 2020-03-24 Натера, Инк. Обнаружение мутаций и плоидности в хромосомных сегментах
BR112016024565A2 (pt) 2014-04-25 2018-01-23 Children's Medical Center Corporation composições e métodos de tratar hemoglobinopatias
WO2016182917A1 (fr) 2015-05-08 2016-11-17 Children's Medical Center Corporation Ciblage des régions fonctionnelles de l'activateur de bcl11a pour la réinduction de l'hémoglobine fœtale
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
KR20180121962A (ko) * 2016-03-22 2018-11-09 발켐 코포레이션 콜린을 포함하는 조성물
US11485996B2 (en) 2016-10-04 2022-11-01 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
CA3049139A1 (fr) 2017-02-21 2018-08-30 Natera, Inc. Compositions, procedes, et kits d'isolement d'acides nucleiques
US11261441B2 (en) 2017-03-29 2022-03-01 Bluebird Bio, Inc. Vectors and compositions for treating hemoglobinopathies
CN110891982B (zh) 2017-04-17 2023-12-22 芝加哥大学 向肠道递送短链脂肪酸以用于人体保健和疾病治疗的聚合物材料
WO2018218135A1 (fr) 2017-05-25 2018-11-29 The Children's Medical Center Corporation Administration de guide bcl11a
CN109722415B (zh) * 2017-10-27 2021-01-26 博雅辑因（北京）生物科技有限公司 一种造血干细胞的培养组合物、培养基以及造血干细胞的培养方法
US11525159B2 (en) 2018-07-03 2022-12-13 Natera, Inc. Methods for detection of donor-derived cell-free DNA
WO2020186216A1 (fr) * 2019-03-14 2020-09-17 Hemoshear Therapeutics, Llc Méthodes de traitement des acidémies organiques
CA3142142A1 (fr) 2019-05-31 2020-12-03 Viracta Subsidiary, Inc. Methodes de traitement de cancers associes a un virus avec des inhibiteurs d'histone desacetylase
EP4041750A4 (fr) * 2019-10-07 2023-11-01 Viracta Subsidiary, Inc. Dosages pour le traitement de hdac à effets secondaires réduits
CN110827950B (zh) * 2019-11-25 2022-10-28 四川大学华西医院 麻醉药物用量的确定方法、模型的训练方法以及模型
US11938143B2 (en) 2021-10-19 2024-03-26 Akirabio, Inc. Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471513A (en) 1966-11-01 1969-10-07 Searle & Co 2-(2-carboxyethyl)-5-phenyl-1-pyrrole-butyric acid and congeners
BE789077A (fr) 1971-09-22 1973-01-15 Nitto Boseki Co Ltd Procede de preparation de derives de pyrimidine
FR2300551A2 (fr) 1975-02-17 1976-09-10 Fabre Sa Pierre Nouveaux
US4008323A (en) 1974-03-25 1977-02-15 Pierre Fabre S.A. Method of reducing cholesterol using certain aromatic keto acids
GB1484413A (en) 1974-04-18 1977-09-01 Kissei Pharmaceutical Aromatic amidocarboxylic acid derivatives
DE2456958A1 (de) 1974-12-03 1976-06-16 Basf Ag 3-(p-biphenylyl)-butyronitril und seine anwendung als arzneimittel
US4031243A (en) 1975-07-03 1977-06-21 Juste, S.A. Quimico-Farmaceutica 2-(4-Isobutyl phenyl)butyric acid, salts thereof, and pharmaceutical compositions containing the same
GB1518764A (en) 1976-03-17 1978-07-26 Soc D Etudes Prod Chimique Isobutyramides their preparation and therapeutic composititions containing them
US4176193A (en) 1977-03-17 1979-11-27 Societe D'etudes De Produits Chimiques Therapeutic isobutyramides
US4732914A (en) 1978-02-13 1988-03-22 The Upjohn Company Prostacyclin analogs
US4234599A (en) 1978-10-04 1980-11-18 Scott Eugene J Van Treatment of skin keratoses with α-hydroxy acids and related compounds
FR2508797B1 (fr) 1981-07-03 1986-03-14 Charles Chany Medicament comprenant le produit de la reaction d'un acide carboxylique en c1 a c6 sur un amino-acide basique
US4704402A (en) 1982-06-12 1987-11-03 University Of Pittsburgh Method of treating sickle cell anemia
GB2126082A (en) 1982-08-12 1984-03-21 Heinrich Schulze Pharmaceutical preparations having analgetic and cytostatic activity
US4894364A (en) 1983-10-26 1990-01-16 Greer Sheldon B Method and materials for sensitizing neoplastic tissue to radiation
US4851229A (en) 1983-12-01 1989-07-25 Alza Corporation Composition comprising a therapeutic agent and a modulating agent
US4671901A (en) 1984-01-26 1987-06-09 Oral-D Orally effective ion chelators
CA1249968A (fr) 1984-04-05 1989-02-14 Kazuo Kigasawa Base pour baume
US4747825A (en) 1984-06-29 1988-05-31 Ferring Laboratories, Inc. Apparatus and methodology for pulsed administration of growth promoting agents
US4613616A (en) 1984-07-20 1986-09-23 Research Corporation Polymeric iron chelators
JPS61155358A (ja) 1984-12-21 1986-07-15 Suntory Ltd ジアリール酪酸誘導体
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4735967A (en) 1985-05-28 1988-04-05 Neesby Torben E Method for desensitizing the gastrointestinal tract from food allergies
DE3534743A1 (de) 1985-09-28 1987-04-02 Beiersdorf Ag Hydrocortisondiester enthaltende o/w-creme
EP0224599A1 (fr) 1985-11-06 1987-06-10 National Patent Development Corporation Solution chimique à utiliser dans le traitement des dents
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US4751244A (en) 1986-04-04 1988-06-14 Merck & Co., Inc. Compounds useful in treating sickle cell anemia
US4731381A (en) 1986-04-04 1988-03-15 Merck & Co., Inc. Method of treating a person for sickle cell anemia
US4699926A (en) 1986-04-04 1987-10-13 Merck & Co., Inc. Compounds useful in treating sickle cell anemia
US4948592A (en) 1986-05-09 1990-08-14 Alza Corporation Pulsed drug delivery
US4723958A (en) 1986-05-23 1988-02-09 Merck & Co., Inc. Pulsatile drug delivery system
US5025029A (en) 1986-10-10 1991-06-18 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin
US4822821A (en) 1986-10-10 1989-04-18 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin
US4965251A (en) 1987-04-03 1990-10-23 The Board Of Regents Of The University Of Washington Pulse treatment of hemoglobinopathies with erythropoietin
US4853388A (en) 1987-05-15 1989-08-01 Pearlman Dale L Method for treating psoriasis with cytotoxic agents
US4820711A (en) 1987-05-15 1989-04-11 Pearlman Dale L Method for treating actinic keratosis with cytotoxic agents
US4849426A (en) 1987-05-15 1989-07-18 Pearlman Dale L Method for treating actinic keratosis with cytotoxic agents
FR2633929B2 (fr) 1987-09-25 1995-05-24 Picardie Universite Derives non toxiques de l'acide n-butyrique, presentant des actions therapeutiques retardees
US5032507A (en) 1987-11-13 1991-07-16 The Salk Institute For Biological Studies Potentiation of erythropoiesis
DE3742222A1 (de) 1987-12-12 1989-06-22 Basf Ag (2r)-aryloxy-3-n-butyroyloxy-propan-2-ole
JP2973322B2 (ja) 1988-01-13 1999-11-08 アリゾナ ボード オブ リーゼンツ 免疫調整剤
US4880624A (en) 1988-03-18 1989-11-14 The Board Of Trustees Of The University Of Illinois Volatile attractants for diabrotica species
US4958592A (en) 1988-08-22 1990-09-25 General Electric Company Resistance heater for diamond production by CVD
US4925873A (en) 1988-09-01 1990-05-15 E. R. Squibb & Sons, Inc. Method of treating skin injuries using thromboxane A2 receptor antagonists
US4997815A (en) 1988-11-01 1991-03-05 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin
EP0371789B1 (fr) 1988-11-29 1997-01-02 Children's Hospital Medical Center Of Northern California Médicament pour l'augmentation de l'hémoglobine foetale
US5137734A (en) 1989-03-22 1992-08-11 Dana Farber Cancer Institute Angiogenic monoglycerides
EP0437577A1 (fr) 1989-08-01 1991-07-24 The University Of Michigan Administration topique de peptides/proteines enfermes dans des liposomes deshidrates/rehydrates
US5039703A (en) 1989-11-16 1991-08-13 Breuer Richard I Method for treating inflammatory bowel disorders
GB8929070D0 (en) 1989-12-22 1990-02-28 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
US5674898A (en) 1990-03-05 1997-10-07 Genzyme Corporation Methods and therapeutic compositions for treating cystic fibrosis
US5258367A (en) 1990-06-29 1993-11-02 University Of Florida Uteroferrin and rose proteins for stimulating hematopoietic cells
SE9002732D0 (sv) 1990-08-24 1990-08-24 Kabivitrum Ab Product containing growth factor
US5216004A (en) 1990-09-13 1993-06-01 Children's Hospital Medical Center Of North California Method for preventing malaria
AU8761391A (en) 1990-09-13 1992-04-15 Children's Hospital Medical Center Of Northern California Method for increasing red blood cell production by treatment with activin or activin-related peptides
US5100647A (en) 1990-10-02 1992-03-31 The Trustees Of The University Of Pennsylvania Method and formulations for the therapy of cystic fibrosis, Bartter's syndrome and secretory diarrheas, and for diuretic treatment
US5674912A (en) 1991-03-01 1997-10-07 Warner-Lambert Company Sunscreen-wound healing compositions and methods for preparing and using same
US5270458A (en) 1991-04-02 1993-12-14 The Trustees Of Princeton University Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
EP0546261A3 (en) 1991-09-12 1993-08-11 American Cyanamid Company Method of treating latent herpes viral infections
WO1993007866A2 (fr) 1991-10-21 1993-04-29 Dvorit Samid Compositions et procedes de traitement et de prevention du cancer, du sida, et de l'anemie
US5635532A (en) 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
CA2107669C (fr) 1992-02-07 2004-06-01 Makoto Okumura Preparation pour le traitement des lesions et des hemorroides
CA2090283A1 (fr) 1992-02-28 1993-08-29 Nobuyuki Hamanaka Derives de l'acide phenoxyacetique
US5439939A (en) 1992-03-17 1995-08-08 Children's Hospital Medical Center Of Northern California Pharmaceutical compositions and methods using isobutyramide for treating betaglobin disorders
US7326535B2 (en) 1993-09-15 2008-02-05 Ortho Diagnostic Systems Inc. Immunoreactive peptides from Epstein-Barr virus
US5366996A (en) 1992-12-07 1994-11-22 Elford Howard L Method of treating hemoglobinopathies
US5403590A (en) 1992-12-21 1995-04-04 New England Deaconess Hospital Corporation Method of pulsatile drug infusion
EP1736152A3 (fr) 1993-10-29 2009-10-07 The Trustees Of Boston University Compositions physiologiquement stables d'acide butyrique, de sels et de dérivés d'acide butyrique pour traiter les plaies
US7888458B1 (en) 1993-11-30 2011-02-15 John B. Harley Diagnostics and therapy of epstein-barr virus in autoimmune disorders
US5952314A (en) 1994-04-01 1999-09-14 Demichele; Stephen Joseph Nutritional product for a person having ulcerative colitis
US5780451A (en) 1994-04-01 1998-07-14 Abbott Laboratories Nutritional product for a person having ulcerative colitis
IL110380A0 (en) 1994-07-20 1994-10-21 Agis Ind 1983 Ltd Antiviral topical pharmaceutical compositions
US6011000A (en) 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
AU6714396A (en) 1995-07-28 1997-02-26 Trustees Of Boston University Methods and compositions for treating cell proliferative disorders
US5912269A (en) 1996-04-30 1999-06-15 Vertex Pharmaceuticals, Inc. Butyrate prodrugs derived from lactic acid
US5883123A (en) 1995-10-06 1999-03-16 Vertex Pharmaceuticals, Inc. Butyrate prodrugs derived from lactic acid
US5763488A (en) 1995-10-30 1998-06-09 Vertex Pharmaceuticals Incorporated Methods and compositions using butyrate esters of threitol
US5846528A (en) 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
US6403647B1 (en) 1996-07-26 2002-06-11 Susan P. Perrine Pulsed administration of compositions for the treatment of blood disorders
EP2298350A3 (fr) * 1996-07-26 2011-06-08 Susan P. Perrine Compositions contenant un agent inducteur ainsi qu'un agent antiviral et destinees au traitement de troubles viraux
US5939456A (en) 1996-07-26 1999-08-17 Perrine; Susan P. Pulsed administration of compositions for the treatment of blood disorders
US6197743B1 (en) 1996-07-26 2001-03-06 The Trustees Of Boston University Compositions and methods for the treatment of viral disorders
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US6043389A (en) 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US5939455A (en) 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
US5932545A (en) 1997-03-17 1999-08-03 Abbott Laboratories Antiangiogenic drug to treat cancer, arthritis and retinopathy
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
JP2002506436A (ja) 1997-06-13 2002-02-26 ザ ジョンズ ホプキンス ユニバーシティー 治療用ナノスフェア
AU774861B2 (en) 1998-02-11 2004-07-08 Douglas V Faller Compositions and methods for the treatment of cystic fibrosis
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
DK1591109T3 (da) * 2004-04-30 2008-10-06 Topotarget Germany Ag Formulering, der omfatter histondeacetylaseinhibitorer, der udviser tofaset frigivelse
US20060069060A1 (en) 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
FR2881746B1 (fr) 2005-02-07 2007-04-13 Centre Nat Rech Scient Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications
US20080075692A1 (en) * 2006-05-09 2008-03-27 Perrine Susan P Methods for treating blood disorders
WO2008028193A2 (fr) 2006-09-01 2008-03-06 Pharmion Corporation Formulations orales d'analogues de cytidine administrées dans le côlon
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
WO2011113013A2 (fr) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Procédés et compositions pour le traitement d'états viraux ou induits par des virus

Also Published As

Publication number Publication date
IL220040A0 (en) 2012-07-31
CN102802412A (zh) 2012-11-28
US20110251149A1 (en) 2011-10-13
EP2509418A4 (fr) 2013-03-20
EP2509418A1 (fr) 2012-10-17
WO2011072086A1 (fr) 2011-06-16
US8618068B2 (en) 2013-12-31
WO2011072086A9 (fr) 2012-09-27
TN2012000270A1 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
MA33899B1 (fr) Procedes et regimes a faible dose pour des troubles des globules rouges
MA38276A1 (fr) Dérivés de l&#39;exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l&#39;obesite, ainsi que la reduction de l&#39;apport alimentaire excessif.
AU2016216625A1 (en) Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
BR112015007985A2 (pt) compostos do carboidrato galactose denteada para o tratamento de nefropatia diabética e distúrbios associados
MX342423B (es) Metodos para usar inhibidores de cotransportadores 1 y 2 de glucosa y sodio.
WO2007081744A3 (fr) Méthodes et compositions pour l&#39;administration de fer
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
WO2012170899A3 (fr) Compositions pharmaceutiques contenant des protéases et procédés pour le traitement de maladies liées au stockage lysosomal
MX2021011222A (es) Métodos y composiciones para mantener la salud renal.
Ataga et al. Advances in new drug therapies for the management of sickle cell disease
Dampier New and emerging treatments for vaso-occlusive pain in sickle cell disease
WO2020106876A3 (fr) Compositions et méthodes pour augmenter l&#39;hémoglobine fœtale et pour traiter la drépanocytose
MX347263B (es) Metodos para incrementar la produccion o actividad de catalasa.
WO2005070077A3 (fr) Procedes d&#39;utilisation de zonisamide comme traitement auxiliaire pour des crises partielles
Carson et al. Transfusion strategies in hematologic and nonhematologic disease
MA31902B1 (fr) Oxazolidinones pour le traitement et/ou la prophylaxie de l&#39;insuffisance cardiaque
Maduell et al. Dialysate calcium individualisation: a pending issue
WO2011056978A3 (fr) Isomères s de l&#39;acide alpha-méthyl-hydrocinnamique pour le traitement de troubles sanguins
WO2012075244A3 (fr) Utilisation d&#39;effecteurs de l&#39;hémoglobine pour améliorer la biodisponibilité de gaz thérapeutiques
Seneff et al. Is GERD a factor in osteonecrosis of the jaw? evidence of pathology linked to g6pd deficiency and sulfomucins
TW200600094A (en) Pharmaceutical compositions for prevention or treatment of disorders of lipid metabolism
Kazuhiko et al. Characteristics of Hemorrhagic Peptic Ulcers in Patients Receiving Antithrombotic/Nonsteroidal Antiinflammatory Drug Therapy
Hong et al. Obturator internus muscle injection therapy in a patient with buttock pain and radiating pain to the lower extremities
Phillips Rhabdomyolysis: case report